TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8545555

Group type: EXPERIMENTAL
Intervention: Autogenous training
Number of subjects: 53

Group type: COMPARATOR
Intervention: Analogic Erickson's techniques
Number of subjects: 53
Study: 8386751

Group type: EXPERIMENTAL
Intervention: Etoposide plus carboplatin (EC)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 270
Study: 3510285

Group type: EXPERIMENTAL
Intervention: Oral high-dose metoclopramide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous high-dose metoclopramide
Number of subjects: 66
Study: 29482677

Group type: EXPERIMENTAL
Intervention: Communication application (app)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 40
Study: 27452837

Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the left temporo-parietal junction (TPJ)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham anodal tDCS over the left temporo-parietal junction (TPJ)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active cathodal tDCS over the left prefrontal cortex (PFC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham cathodal tDCS over the left prefrontal cortex (PFC)
Number of subjects: 42
Study: 26629666

Group type: EXPERIMENTAL
Intervention: Professional training for nurses
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no professional training)
Number of subjects: 17
Study: 23216231

Group type: EXPERIMENTAL
Intervention: Elimination diet
Number of subjects: 21
Study: 21689029

Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser
Number of subjects: 2

Group type: COMPARATOR
Intervention: 1064-nm Nd:YAG laser
Number of subjects: 2
Study: 19134274

Group type: EXPERIMENTAL
Intervention: Compliance group (HCTZ + spironolactone or captopril)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Non-compliance group (HCTZ + spironolactone or captopril)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Compliance group
Number of subjects: 853

Group type: COMPARATOR
Intervention: Non-compliance group
Number of subjects: 853
Study: 17263269

Group type: EXPERIMENTAL
Intervention: 20 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group A)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 ml/kg of intravenous isotonic electrolyte solution (0.9% sodium chloride) (group B)
Number of subjects: 200
Study: 12671771

Group type: EXPERIMENTAL
Intervention: Heavyweight, rigid polypropylene mesh (group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Heavyweight, softer polypropylene mesh (group B)
Number of subjects: 40
Study: 10616846

Group type: EXPERIMENTAL
Intervention: HMW apo(a) phenotypes
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control subjects with matched apo(a) phenotypes
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: LMW apo(a) phenotypes
Number of subjects: 227
Study: 7555621

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 2303557

Group type: EXPERIMENTAL
Intervention: Visit group (early sibling visitation during the first week of neonatal life)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Comparison group (visited only after the study was completed, 3 weeks after birth)
Number of subjects: 31
Study: 7250779

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2‐alpha gel (2.5 mg, intracervically)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 tablets (1 mg, orally)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 581

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 581
Study: 30821167

Group type: EXPERIMENTAL
Intervention: Montelukast, fexofenadine, and fluticasone nasal spray (Mo-Fex-Flu)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Cetirizine and fluticasone nasal spray (Cet-Flu)
Number of subjects: 428
Study: 28125977

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for medication review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 0
Study: 26148314

Group type: EXPERIMENTAL
Intervention: Resistance and impact training
Number of subjects: 51

Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 51
Study: 23702393

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.2 mg/kg every 2 weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.1 mg/kg/week
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Agalsidase alfa 0.2 mg/kg/week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21658010

Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) glutamine supplementation, 0.283 g glutamine/kg body weight/24 h for the entire ICU stay
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 413
Study: 19701107

Group type: EXPERIMENTAL
Intervention: Canfosfamide (400-1000 mg/m2 IV) with carboplatin (AUC 6 IV) and paclitaxel (200 mg/m2 IV)
Number of subjects: 129
Study: 16735495

Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/d
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15330905

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (3 or 5 million units thrice a week) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (5 million units) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (3 million units) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (higher dose) plus ribavirin (1,000-1,200 mg)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b and ribavirin
Number of subjects: 56
Study: 10756578

Group type: EXPERIMENTAL
Intervention: Misti Gold II prostheses
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline-filled prostheses
Number of subjects: 41
Study: 9283926

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Fluoxetine (in patients with serious physical illness who completed 5 or more weeks)
Number of subjects: 82
Study: 7942576

Group type: EXPERIMENTAL
Intervention: 800 mg dl alpha‐tocopheryl acetate daily for 30 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 2465180

Group type: EXPERIMENTAL
Intervention: Microscopic examination of morning sputum
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Microscopic examination of 24 h sputum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cultural examination of homogenized sputum
Number of subjects: 12

Group type: COMPARATOR
Intervention: Homogenization with 2% pancreatin
Number of subjects: 12
Study: 30921234

Group type: EXPERIMENTAL
Intervention: Ginger consumption (1600-4000mg daily)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control group (no ginger consumption)
Number of subjects: 454
Study: 28504480

Group type: EXPERIMENTAL
Intervention: Microneedling (28 patients, one session every 4 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (34 patients, one session every 2 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of microneedling and platelet-rich plasma (28 patients, alternative sessions every 2 weeks for a maximum of six sessions)
Number of subjects: 90
Study: 26271815

Group type: EXPERIMENTAL
Intervention: Peer support (structured home visits)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Peer support (structured home visits) among care-naïve participants
Number of subjects: 442

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 442

Group type: COMPARATOR
Intervention: Standard of care among care-naïve participants
Number of subjects: 442
Study: 23349407

Group type: EXPERIMENTAL
Intervention: Rehabilitation plus early ACL reconstruction
Number of subjects: 121

Group type: COMPARATOR
Intervention: Rehabilitation plus optional delayed ACL reconstruction
Number of subjects: 121
Study: 21419002

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional antiparkinsonian drug therapy alone (Control)
Number of subjects: 55
Study: 18211932

Group type: EXPERIMENTAL
Intervention: Topical levofloxacin 0.3%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Topical and oral levofloxacin (250 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Topical ofloxacin 0.3%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral ofloxacin 400 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral ciprofloxacin 400 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral levofloxacin 250 mg
Number of subjects: 48
Study: 16570297

Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (0.8 mg/kg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study: 14610980

Group type: EXPERIMENTAL
Intervention: Knowledge Enhances Your Safety (KEYS) curriculum
Number of subjects: 0
Study: 10731187

Group type: EXPERIMENTAL
Intervention: Plant sterol or stanol margarines (2 g added to an average daily portion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in low density lipoprotein cholesterol
Number of subjects: 0
Study: 8632939

Group type: EXPERIMENTAL
Intervention: Pavement stencil intervention group
Number of subjects: 319

Group type: COMPARATOR
Intervention: Education-only group
Number of subjects: 319
Study: 1534771

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 63
Study: 3937510

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablet, twice daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177

Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 177
Study: 30624586

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril and 0.8 mg folic acid
Number of subjects: 620

Group type: COMPARATOR
Intervention: 10 mg enalapril alone
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Plasma retinol (per 10-μg/dL increment)
Number of subjects: 620
Study: 30252845

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 24
Study: 26507194

Group type: EXPERIMENTAL
Intervention: Clonidine (150/175 μg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.2 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24060350

Group type: EXPERIMENTAL
Intervention: Reduced standard treatment plus a Web‐based psychosocial intervention (Therapeutic Education System - TES)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 160
Study: 22038880

Group type: EXPERIMENTAL
Intervention: Hypopressive exercises associated with pelvic floor muscle training (HE + PFMT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 20638338

Group type: EXPERIMENTAL
Intervention: Acupuncture (traditional Chinese medicine)
Number of subjects: 635

Group type: COMPARATOR
Intervention: Placebo acupuncture (validated placebo needle)
Number of subjects: 635
Study: 17975152

Group type: EXPERIMENTAL
Intervention: Docetaxel every three weeks
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Docetaxel weekly
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 1006
Study: 15844060

Group type: EXPERIMENTAL
Intervention: Topical imiquimod 5% cream (Aldara; 3M Pharmaceuticals)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 40
Study: 11973192

Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion
Number of subjects: 54
Study: 10392063

Group type: EXPERIMENTAL
Intervention: 1.1% IPAA (Nutrineal, Baxter Healthcare Ltd) administered once per day for 18 weeks
Number of subjects: 1
Study: 7658090

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 30
Study: 2663834

Group type: EXPERIMENTAL
Intervention: Haloperidol, 0.25 to 4.0 mg/day (M = 0.844) for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1095996

Group type: EXPERIMENTAL
Intervention: Equine esterified estrogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic esterfield estrogens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no estrogen therapy)
Number of subjects: 0
Study: 30763426

Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0
Study: 29200840

Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol 5/5 μg
Number of subjects: 1152

Group type: COMPARATOR
Intervention: tiotropium 5 μg
Number of subjects: 1152

Group type: COMPARATOR
Intervention: olodaterol 5 μg
Number of subjects: 1152
Study: 26431648

Group type: EXPERIMENTAL
Intervention: Holistic nursing combined with conventional therapy (test group I)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oxygen-driving and atomized Mucosolvan inhalation combined with holistic nursing (test group II)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 90
Study: 24103895

Group type: EXPERIMENTAL
Intervention: Live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine (rHPIV3cp45)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21576828

Group type: COMPARATOR
Intervention: Beta-blockers (atenolol, 25-50mg/day, n=60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Calcium channel antagonists (benidipine, 4-8 mg/day, n=60)
Number of subjects: 120
Study: 18801626

Group type: EXPERIMENTAL
Intervention: Intensive support programme for community pharmacies to send discontinuation letters to patients.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group with a written manual for pharmacies.
Number of subjects: 90
Study: 17397739

Group type: EXPERIMENTAL
Intervention: Zernike treatment tables
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fourier treatment tables
Number of subjects: 32
Study: 14671236

Group type: EXPERIMENTAL
Intervention: Glucose/potassium/insulin (GKI) infusions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusions (control)
Number of subjects: 0
Study: 11317693

Group type: EXPERIMENTAL
Intervention: p53 autoantibodies (p53‐Ab) detected in serum
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: p53 autoantibodies (p53‐Ab)
Number of subjects: 130
Study: 9399737

Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol 0.1 mg/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 0.1 mg and medroxyprogesterone acetate 2.5 mg/day
Number of subjects: 20
Study: 7956276

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (150 mg/kg IV over 15 mins, then 12.5 mg/hr continuous infusion for 90 mins)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (entire group)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine responders
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 3294946

Group type: EXPERIMENTAL
Intervention: Liquid formulation of 8‐methoxypsoralen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crystalline formulation of 8‐methoxypsoralen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study: 29479974

Group type: EXPERIMENTAL
Intervention: Nefopam (120 mg) with fentanyl (20 µg/kg)
Number of subjects: 92
Study: 27465597

Group type: EXPERIMENTAL
Intervention: Live attenuated bacterial vaccines (typhoid and enterotoxigenic Escherichia coli)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Micronutrient supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Rotavirus vaccine
Number of subjects: 8
Study: 24996498

Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-foam sonography (HyFoSy)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Serial hysterosalpingography (HSG)
Number of subjects: 40
Study: 22837377

Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure treatment
Number of subjects: 113

Group type: COMPARATOR
Intervention: Sham continuous positive airway pressure treatment
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Active continuous positive airway pressure treatment (crossover phase)
Number of subjects: 113
Study: 20724565

Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE; α(1))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clonidine (CL; α(2))
Number of subjects: 19
Study: 18450845

Group type: EXPERIMENTAL
Intervention: Antenatal steroids > 7 days before delivery (remote group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Antenatal steroids 1 to 7 days before delivery (ideal group)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Antenatal steroids 8 to 14 days before delivery (remote group subgroup)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Antenatal steroids > 14 days before delivery (remote group subgroup)
Number of subjects: 56
Study: 16141012

Group type: EXPERIMENTAL
Intervention: Laser-assisted lidocaine application (Er:YAG laser, fluence 3.5 J/cm², pulse width 600 microseconds, spot diameter 6 mm)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham laser application
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison of pain levels
Number of subjects: 30
Study: 12685512

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10069551

Group type: EXPERIMENTAL
Intervention: Ritanserin 2.5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg/day
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Ritanserin 10 mg/day
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 7745335

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate and adrenaline paste applied to the tonsillar fossae during tonsillectomy
Number of subjects: 98
Study: 2033414

Group type: EXPERIMENTAL
Intervention: Monthly pulses of vincristine-prednisone (VCR-PDN) during maintenance therapy
Number of subjects: 631

Group type: COMPARATOR
Intervention: Standard therapy with mercaptopurine (6MP) and methotrexate (MTX) alone
Number of subjects: 631
Study: 7343274

Group type: EXPERIMENTAL
Intervention: Endralazine (initial dose 2.5 mg three times daily, increased to a maximum of 50 mg daily)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endralazine
Number of subjects: 27
Study: 28776930

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for youth at high risk (FFT-HR), 12 sessions in 4 months of family psychoeducation and skills training.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Enhanced care (EC), 6 individual and family sessions over 4 months.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Family-focused treatment for youth at high risk (FFT-HR)
Number of subjects: 133
Study: 28351509

Group type: EXPERIMENTAL
Intervention: Calcium intake >95% probability of adequate intake (PA) maintained over 2 years
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Calcium intake >95% probability of adequate intake (PA) maintained over 3 years
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Calcium intake at 6 years
Number of subjects: 179

Group type: COMPARATOR
Intervention: Calcium intake <95% probability of adequate intake (PA)
Number of subjects: 179
Study: 27926458

Group type: EXPERIMENTAL
Intervention: 3g/d of long‐chain omega‐3 fatty acids (1856mg EPA and 1232mg DHA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: High‐oleic safflower oil (control)
Number of subjects: 66
Study: 26492776

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less lipid-lowering therapy
Number of subjects: 0
Study: 22992964

Group type: EXPERIMENTAL
Intervention: Low flow anaesthesia (0.8 L min(‐1) air-oxygen-sevoflurane (1-3 MAC))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High flow anaesthesia (6 L min‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low flow anaesthesia (0.8 L min(‐1)) in non-cancer patients
Number of subjects: 75
Study: 19168444

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17466785

Group type: EXPERIMENTAL
Intervention: ACUSEAL patch
Number of subjects: 200

Group type: COMPARATOR
Intervention: Finesse patch
Number of subjects: 200
Study: 16401653

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.5mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Modafinil (200mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of pramipexole and modafinil
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12514291

Group type: EXPERIMENTAL
Intervention: Lactation counseling
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no lactation counseling)
Number of subjects: 188
Study: 11044538

Group type: EXPERIMENTAL
Intervention: Combination pill
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mini-pill
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 8793454

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Number of subjects: 15
Study: 1355952

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6337005

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Metrizamide
Number of subjects: 40
Study: 31801164

Group type: EXPERIMENTAL
Intervention: Self-help app for Syrian refugees with posttraumatic stress
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Snowball sampling recruitment strategy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Multi-strategic recruitment approach
Number of subjects: 140